2cureX: Progress in the making - Redeye

Redeye comments on 2cureX’s Q3’22 report. The company highlights positive results from an independent survey investigating the need for new tools to support therapy decision-making. Furthermore, 2cureX addresses the challenges with the clinical uptake of new medical technologies. We will return with a research update, where we will review our financial forecasts and fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/865621/2curex-q3-progress-in-the-making?utm_source=finwire&utm_medium=RSS